{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T17:42:06.302197+00:00","company":{"ticker":"LYEL","cik":1806952,"company_name":"Lyell Immunopharma, Inc."},"pagination":{"limit":100,"returned":33,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"ma_counterparty":[{"display_name":"ImmPACT Bio USA Inc.","detail":"acquisition","count":1,"first_seen":"2024-10-31T23:59:59+00:00","last_seen":"2024-10-31T23:59:59+00:00","evidence_fact_ids":[109825]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"32b56b2201169158c72a25b01e2c0554a4208660","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2026-06-15T20:05:50+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Advisory vote on the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement","proposal_type":"say_on_pay","results":[{"broker_non_votes":"3,429,286","subject":null,"votes_abstain":"410,709","votes_against":"6,613","votes_for":"11,860,218","votes_withheld":null}]},"claim":"Lyell Immunopharma, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement at the 2026-06-10 meeting.","evidence_excerpt":"To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Total 11,860,218 6,613 410,709 3,429,286 15,706,826","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-271071","anchor_url":"https://secwatch.observer/filing/0001193125-26-271071#claim-32b56b2201169158c72a25b01e2c0554a4208660","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f516b585021a182e2a1aea7c48021be30369bcaa","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2026-06-15T20:05:50+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"1,721","votes_against":"30,758","votes_for":"15,674,347","votes_withheld":null}]},"claim":"Lyell Immunopharma, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.","evidence_excerpt":"To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Total 15,674,347 30,758 1,721 15,706,826","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-271071","anchor_url":"https://secwatch.observer/filing/0001193125-26-271071#claim-f516b585021a182e2a1aea7c48021be30369bcaa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ac96924132db81d345552d0e1dcc9997b5a92fcf","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2026-06-15T20:05:50+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Election of Class II directors to hold office until the Company's 2029 annual meeting of stockholders","proposal_type":"director_election","results":[{"broker_non_votes":"3,429,286","subject":"Richard Klausner, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"12,177,913","votes_withheld":"99,627"},{"broker_non_votes":"3,429,286","subject":"Otis Brawley, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"11,866,210","votes_withheld":"411,330"},{"broker_non_votes":"3,429,286","subject":"William Rieflin","votes_abstain":null,"votes_against":null,"votes_for":"12,192,547","votes_withheld":"84,993"}]},"claim":"Lyell Immunopharma, Inc. shareholders approved Election of Class II directors to hold office until the Company's 2029 annual meeting of stockholders at the 2026-06-10 meeting.","evidence_excerpt":"To elect the following Class II directors to hold office until the Company’s 2029 annual meeting of stockholders. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Richard Klausner, M.D. 12,177,913 99,627 3,429,286 15,706,826 Otis Brawley, M.D. 11,866,210 411,330 3,429,286 15,706,826 William Rieflin 12,192,547 84,993 3,429,286 15,706,826","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-271071","anchor_url":"https://secwatch.observer/filing/0001193125-26-271071#claim-ac96924132db81d345552d0e1dcc9997b5a92fcf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm"},{"fact_type":"earnings_release","fact_key":"b50578459726e98ba159be0f1ecc9e727eb45933","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $24.2 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":null},"claim":"Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2026 results: net income net loss of $24.2 million.","evidence_excerpt":"Lyell reported a net loss of $24.2 million for the first quarter ended March 31, 2026, compared to a net loss of $52.2 million for the same period in 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-031269","anchor_url":"https://secwatch.observer/filing/0001628280-26-031269#claim-b50578459726e98ba159be0f1ecc9e727eb45933","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828026031269/0001628280-26-031269-index.htm"},{"fact_type":"earnings_release","fact_key":"a65362b8db701ad9fd5b861d4e8b8bf2beaf9c06","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2026-03-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and full year ended December 31, 2025","report_date":"2026-03-12","result_type":"reported_results","revenue_text":null},"claim":"Lyell Immunopharma, Inc. reported financial results for the quarter and full year ended December 31, 2025.","evidence_excerpt":"On March 12, 2026, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-017244","anchor_url":"https://secwatch.observer/filing/0001628280-26-017244#claim-a65362b8db701ad9fd5b861d4e8b8bf2beaf9c06","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/0001628280-26-017244-index.htm"},{"fact_type":"governance_change","fact_key":"fbfd11a78bbfce5929126adaca18a8e35fe6618b","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-12-05T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-12-03","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to modernize stockholder proposal procedures, clarify update rules, conform notice provisions to DGCL Section 232, simplify voting standards, and conform stockholder list requirements to DGCL Section 219."},"claim":"Lyell Immunopharma, Inc.: Amended and restated bylaws to modernize stockholder proposal procedures, clarify update rules, conform notice provisions to DGCL Section 232, simplify voting standards, and conform stockholder list requirements to DGCL Section 219 (effective 2025-12-03).","evidence_excerpt":"On December 3, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws (the “Amended Bylaws”), effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-309621","anchor_url":"https://secwatch.observer/filing/0001193125-25-309621#claim-fbfd11a78bbfce5929126adaca18a8e35fe6618b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525309621/0001193125-25-309621-index.htm"},{"fact_type":"executive_change","fact_key":"5c18a9128c","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-06-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-09","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mark Bachleda was appointed as Director at Lyell Immunopharma, Inc..","evidence_excerpt":"on June 9, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) increased the authorized size of the Board from seven directors to eight directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mark Bachleda, Pharm.D., M.B.A., to the Board as a Class I director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-137853","anchor_url":"https://secwatch.observer/filing/0001193125-25-137853#claim-5c18a9128c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525137853/0001193125-25-137853-index.htm"},{"fact_type":"restructuring_charge","fact_key":"6d65b754a9a48665dc432e9ed7350f54aedccd8b","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-04-01T23:59:59+00:00","payload":{"affected_area":"West Hills manufacturing facility","charge_text":"$3.0 million to $4.0 million","effective_date":"2025-03-31","event_type":"restructuring","headcount_text":"approximately 73 employees","item_codes_triggered":["2.05"]},"claim":"Lyell Immunopharma, Inc. announced a restructuring with charges of $3.0 million to $4.0 million affecting West Hills manufacturing facility (approximately 73 employees).","evidence_excerpt":"On March 31, 2025, Lyell’s Board of Directors (the “Board”) approved the closure of the West Hills manufacturing facility acquired as part of Lyell’s acquisition of ImmPACT Bio in 2024. The Board also approved the reduction of the Company’s workforce in West Hills by approximately 73 employees related to such closure. In connection with these actions, the Company expects to incur aggregate expenses of between $3.0 million to $4.0 million, related to severance, benefits, payroll taxes, and other workforce reduction costs, which are expected to be recognized primarily in the second and third quarters of 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-070521","anchor_url":"https://secwatch.observer/filing/0001193125-25-070521#claim-6d65b754a9a48665dc432e9ed7350f54aedccd8b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525070521/0001193125-25-070521-index.htm"},{"fact_type":"executive_change","fact_key":"edfd6801a4","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-04-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-13","interim":false,"role":"Chief Business Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Matthew Lang resigned as Chief Business Officer at Lyell Immunopharma, Inc..","evidence_excerpt":"On March 27, 2025, Matthew Lang, J.D. notified the Company of his resignation as Chief Business Officer and from all other offices of the Company, effective April 13, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-070521","anchor_url":"https://secwatch.observer/filing/0001193125-25-070521#claim-edfd6801a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525070521/0001193125-25-070521-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"07e608179b3c578414444b022c2fe026fcddfb88","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-01-24T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-07-22","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-01-23","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(a)(1)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Lyell Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar da","confidence":0.97,"filing_url":"https://secwatch.observer/filing/0001193125-25-012249","anchor_url":"https://secwatch.observer/filing/0001193125-25-012249#claim-07e608179b3c578414444b022c2fe026fcddfb88","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"1383847858e313a1029bbbd3833b65109d3c7cb0","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-01-24T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-07-22","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-01-23","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(a)(1)"]},"claim":"Lyell Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-012249","anchor_url":"https://secwatch.observer/filing/0001193125-25-012249#claim-1383847858e313a1029bbbd3833b65109d3c7cb0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm"},{"fact_type":"executive_change","fact_key":"8a1986545b","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-11-26T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-22","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Hans Bishop resigned as Director at Lyell Immunopharma, Inc..","evidence_excerpt":"On November 22, 2024, Hans Bishop resigned as a member of the Board of Directors (the “Board”) and the Nominating and Corporate Governance Committee of the Board of Lyell Immunopharma, Inc. (the “Company”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-266101","anchor_url":"https://secwatch.observer/filing/0001193125-24-266101#claim-8a1986545b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524266101/0001193125-24-266101-index.htm"},{"fact_type":"ma_transaction","fact_key":"c78babdcd1ae904e58af79ea56cd77f666c2ce7b","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-10-31T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2024-10-31","consideration_text":"$30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock","counterparty":"ImmPACT Bio USA Inc.","effective_date":"2024-10-31","item_codes_triggered":["2.01"]},"claim":"Lyell Immunopharma, Inc. completed an acquisition involving ImmPACT Bio USA Inc. for $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock (closed 2024-10-31).","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, on the Closing Date, the Company acquired all of the outstanding equity interests of ImmPACT in exchange for an upfront payment of $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock. The acquisition was effected via a","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-248760","anchor_url":"https://secwatch.observer/filing/0001193125-24-248760#claim-c78babdcd1ae904e58af79ea56cd77f666c2ce7b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/0001193125-24-248760-index.htm"},{"fact_type":"executive_change","fact_key":"6ff27901a9","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-10-31T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-31","interim":false,"role":"Class III director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sumant Ramachandra was appointed as Class III director at Lyell Immunopharma, Inc..","evidence_excerpt":"Sumant Ramachandra, M.D., Ph.D., who was the Chief Executive Officer and a director of ImmPACT prior to the consummation of the Merger, was appointed as a Class III director to the Board of Directors of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-248760","anchor_url":"https://secwatch.observer/filing/0001193125-24-248760#claim-6ff27901a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/0001193125-24-248760-index.htm"},{"fact_type":"earnings_release","fact_key":"ac4b75a14164bc4af56b019ceab92c26c3a3a1df","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $60.7 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":null},"claim":"Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $60.7 million.","evidence_excerpt":"Lyell reported a net loss of $60.7 million for the first quarter ended March 31, 2024, compared to a net loss of $67.0 million for the same period in 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-020466","anchor_url":"https://secwatch.observer/filing/0001628280-24-020466#claim-ac4b75a14164bc4af56b019ceab92c26c3a3a1df","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/0001628280-24-020466-index.htm"},{"fact_type":"earnings_release","fact_key":"7850c648b07b13c44d118c0464c46bb43551c577","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $60.7 million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":null},"claim":"Lyell Immunopharma, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $60.7 million.","evidence_excerpt":"On May 6, 2024, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-020466","anchor_url":"https://secwatch.observer/filing/0001628280-24-020466#claim-7850c648b07b13c44d118c0464c46bb43551c577","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/0001628280-24-020466-index.htm"},{"fact_type":"earnings_release","fact_key":"b7ecf30e7aa5c2b8c33dbf884689b4d22b6265ce","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$52.9 million","period_text":"the fourth quarter and full year ended December 31, 2023","report_date":"2024-02-28","result_type":"reported_results","revenue_text":null},"claim":"Lyell Immunopharma, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $52.9 million.","evidence_excerpt":"Fourth Quarter and Full Year 2023 Financial Results Lyell reported a net loss of $52.9 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-007579","anchor_url":"https://secwatch.observer/filing/0001628280-24-007579#claim-b7ecf30e7aa5c2b8c33dbf884689b4d22b6265ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024007579/0001628280-24-007579-index.htm"},{"fact_type":"earnings_release","fact_key":"18a832d78a475d2c3d6e540daf96a53977129685","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$50.9 million","period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-07","result_type":"reported_results","revenue_text":"approximately zero"},"claim":"Lyell Immunopharma, Inc. reported the third quarter ended September 30, 2023 results: revenue approximately zero, net income $50.9 million.","evidence_excerpt":"Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-037346","anchor_url":"https://secwatch.observer/filing/0001628280-23-037346#claim-18a832d78a475d2c3d6e540daf96a53977129685","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023037346/0001628280-23-037346-index.htm"},{"fact_type":"earnings_release","fact_key":"0bc303036c518b3f65ddeae88594cd458707921a","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-08-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $63.9 million","period_text":"the quarter ended June 30, 2023","report_date":"2023-08-08","result_type":"reported_results","revenue_text":"approximately zero"},"claim":"Lyell Immunopharma, Inc. reported the quarter ended June 30, 2023 results: revenue approximately zero, net income net loss of $63.9 million.","evidence_excerpt":"Lyell reported a net loss of $63.9 million for the second quarter ended June 30, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-23-028189","anchor_url":"https://secwatch.observer/filing/0001628280-23-028189#claim-0bc303036c518b3f65ddeae88594cd458707921a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023028189/0001628280-23-028189-index.htm"},{"fact_type":"shareholder_vote","fact_key":"cc5eae02ac84131eccfc172ba243048a86503953","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Advisory vote on preferred frequency of stockholder advisory votes on executive compensation","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"33,914,284","subject":null,"votes_abstain":"10,939,688","votes_against":null,"votes_for":"142,962,684","votes_withheld":null}]},"claim":"Lyell Immunopharma, Inc. shareholders approved Advisory vote on preferred frequency of stockholder advisory votes on executive compensation at the 2023-06-16 meeting.","evidence_excerpt":"To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes to approve the compensation of the Company’s named executive officers. The voting results were as follows: Vote For Every One Year Vote For Every Two Years Vote For Every Three Years Abstentions Broker Non-Votes Total 142,962,684 695 33,332 10,939,688 33,914,284 187,850,683","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-171240","anchor_url":"https://secwatch.observer/filing/0001193125-23-171240#claim-cc5eae02ac84131eccfc172ba243048a86503953","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/0001193125-23-171240-index.htm"},{"fact_type":"shareholder_vote","fact_key":"830248f32720e6d08e41465fc93120f64ff0c051","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Advisory vote to approve compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"33,914,284","subject":null,"votes_abstain":"19,180,844","votes_against":"3,278,721","votes_for":"131,476,834","votes_withheld":null}]},"claim":"Lyell Immunopharma, Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2023-06-16 meeting.","evidence_excerpt":"To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Total 131,476,834 3,278,721 19,180,844 33,914,284 187,850,683","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-171240","anchor_url":"https://secwatch.observer/filing/0001193125-23-171240#claim-830248f32720e6d08e41465fc93120f64ff0c051","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/0001193125-23-171240-index.htm"},{"fact_type":"shareholder_vote","fact_key":"42b352166a8d8aca9052bf6823c8cbeba43f8559","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"39,312","votes_against":"16,913","votes_for":"187,794,458","votes_withheld":null}]},"claim":"Lyell Immunopharma, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-16 meeting.","evidence_excerpt":"To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Total 187,794,458 16,913 39,312 187,850,683","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-171240","anchor_url":"https://secwatch.observer/filing/0001193125-23-171240#claim-42b352166a8d8aca9052bf6823c8cbeba43f8559","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/0001193125-23-171240-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d4fae927ced9b1f888c964a512c73c32686f33a2","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-16","outcome":"passed","proposal_text":"Election of three Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"33,914,284","subject":"Richard Klausner, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"150,646,318","votes_withheld":"3,290,081"},{"broker_non_votes":"33,914,284","subject":"Otis Brawley, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"143,059,192","votes_withheld":"10,877,207"},{"broker_non_votes":"33,914,284","subject":"William Rieflin","votes_abstain":null,"votes_against":null,"votes_for":"150,032,005","votes_withheld":"3,904,394"}]},"claim":"Lyell Immunopharma, Inc. shareholders approved Election of three Class II directors at the 2023-06-16 meeting.","evidence_excerpt":"To elect the following three Class II directors to hold office until the Company’s 2026 annual meeting of stockholders. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Richard Klausner, M.D. 150,646,318 3,290,081 33,914,284 187,850,683 Otis Brawley, M.D. 143,059,192 10,877,207 33,914,284 187,850,683 William Rieflin 150,032,005 3,904,394 33,914,284 187,850,683","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-171240","anchor_url":"https://secwatch.observer/filing/0001193125-23-171240#claim-d4fae927ced9b1f888c964a512c73c32686f33a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312523171240/0001193125-23-171240-index.htm"},{"fact_type":"earnings_release","fact_key":"29444f6c0f744effafd64c4a781f1b54eb82561a","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$67.0 million net loss","period_text":"the first quarter ended March 31, 2023","report_date":"2023-05-04","result_type":"reported_results","revenue_text":"$0.1 million"},"claim":"Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2023 results: revenue $0.1 million, net income $67.0 million net loss.","evidence_excerpt":"First Quarter Financial Results Lyell reported a net loss of $67.0 million for the first quarter ended March 31, 2023, compared to a net loss of $68.1 million for the same period in 2022. Non‐GAAP net loss, which excludes non-cash stock-based compensation, non‐cash expenses related to the change in the estimated fair value of success payment liabilities and certain non-cash investment gains and charges, was $44.8 million for the first quarter ended March 31, 2023, compared to $50.0 million for the same period in 2022. Revenue • Revenue was $0.1 million for the first quarter ended March 31, 2023 compared to $0.6 million for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-015733","anchor_url":"https://secwatch.observer/filing/0001628280-23-015733#claim-29444f6c0f744effafd64c4a781f1b54eb82561a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023015733/0001628280-23-015733-index.htm"},{"fact_type":"earnings_release","fact_key":"34333e367f9ddde7605ece652a9163a80a27a58e","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$183.1 million","period_text":"the year ended December 31, 2022","report_date":"2023-02-28","result_type":"reported_results","revenue_text":null},"claim":"Lyell Immunopharma, Inc. reported the year ended December 31, 2022 results: net income $183.1 million.","evidence_excerpt":"Lyell reported a net loss of $8.4 million and $183.1 million for the fourth quarter and year ended December 31, 2022,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-005554","anchor_url":"https://secwatch.observer/filing/0001628280-23-005554#claim-34333e367f9ddde7605ece652a9163a80a27a58e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/0001628280-23-005554-index.htm"},{"fact_type":"earnings_release","fact_key":"c8087b7800f6d0913e15150f7f2c5a28a1f82f06","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$8.4 million","period_text":"the fourth quarter ended December 31, 2022","report_date":"2023-02-28","result_type":"reported_results","revenue_text":null},"claim":"Lyell Immunopharma, Inc. reported the fourth quarter ended December 31, 2022 results: net income $8.4 million.","evidence_excerpt":"Lyell reported a net loss of $8.4 million and $183.1 million for the fourth quarter and year ended December 31, 2022,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-005554","anchor_url":"https://secwatch.observer/filing/0001628280-23-005554#claim-c8087b7800f6d0913e15150f7f2c5a28a1f82f06","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/0001628280-23-005554-index.htm"},{"fact_type":"executive_change","fact_key":"94fc373c49","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-12-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-15","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Lynn Seely was appointed as President and Chief Executive Officer at Lyell Immunopharma, Inc..","evidence_excerpt":"On December 14, 2022, Dr. Seely entered into an offer of employment with the Company (the “Seely Offer Letter”), pursuant to which she commenced her role as the Company’s President and Chief Executive Officer on December 15, 2022","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-22-307296","anchor_url":"https://secwatch.observer/filing/0001193125-22-307296#claim-94fc373c49","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/0001193125-22-307296-index.htm"},{"fact_type":"executive_change","fact_key":"2ad474fd8c","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-12-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-12-15","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Lynn Seely","successor_named":true},"claim":"Elizabeth Homans resigned as Chief Executive Officer at Lyell Immunopharma, Inc..","evidence_excerpt":"On December 15, 2022, Lyell Immunopharma, Inc. (the “Company”) announced that Ms. Elizabeth Homans would step down from her position as Chief Executive Officer and as a member of the Board of Directors (the “Board”) of the Company effective December 15, 2022","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-22-307296","anchor_url":"https://secwatch.observer/filing/0001193125-22-307296#claim-2ad474fd8c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/0001193125-22-307296-index.htm"},{"fact_type":"earnings_release","fact_key":"0e95a46eec28987301aa08f9f3366ba90b349a5e","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter of 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":null},"claim":"Lyell Immunopharma, Inc. reported financial results for third quarter of 2022.","evidence_excerpt":"On November 8, 2022, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-22-028908","anchor_url":"https://secwatch.observer/filing/0001628280-22-028908#claim-0e95a46eec28987301aa08f9f3366ba90b349a5e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022028908/0001628280-22-028908-index.htm"},{"fact_type":"executive_change","fact_key":"fc4baeba29","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2021-10-28T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2021-11-01","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Stephen Hill changed role as Chief Operating Officer at Lyell Immunopharma, Inc..","evidence_excerpt":"On October 23, 2021, the compensation committee (the “Compensation Committee) of the board of directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) approved the promotion of Stephen Hill, the Company’s Chief Technical Operations Officer, to the position of Chief Operating Officer, to serve in such position until his successor is appointed or until his earlier resignation or removal. Such promotion will be effective on November 1, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-309692","anchor_url":"https://secwatch.observer/filing/0001193125-21-309692#claim-fc4baeba29","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521309692/0001193125-21-309692-index.htm"},{"fact_type":"executive_change","fact_key":"21059c699d","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2021-10-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-10-01","interim":false,"role":"Executive Chairman","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Richard Klausner resigned as Executive Chairman at Lyell Immunopharma, Inc..","evidence_excerpt":"On September 29, 2021, Dr. Klausner informed the Company that he will be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2021.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-21-288697","anchor_url":"https://secwatch.observer/filing/0001193125-21-288697#claim-21059c699d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521288697/0001193125-21-288697-index.htm"},{"fact_type":"executive_change","fact_key":"ec3e229ae5","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2021-09-30T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-09-29","interim":true,"role":"interim Chair of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Cathy Friedman was elected as interim Chair of the Board at Lyell Immunopharma, Inc..","evidence_excerpt":"The Board has elected Cathy Friedman, its lead independent director, to serve as the interim Chair of the Board during Dr. Klausner’s absence.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-287960","anchor_url":"https://secwatch.observer/filing/0001193125-21-287960#claim-ec3e229ae5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521287960/0001193125-21-287960-index.htm"},{"fact_type":"executive_change","fact_key":"e2cedd99e6","cik":1806952,"ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","filed_at":"2021-09-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-10-01","interim":false,"role":"Chair of the Board","role_category":"chair","successor_name":"Cathy Friedman","successor_named":true},"claim":"Dr. Richard Klausner resigned as Chair of the Board at Lyell Immunopharma, Inc..","evidence_excerpt":"On September 29, 2021, Dr. Richard Klausner, the Chair of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) informed the Company that (a) he will take a temporary medical leave of absence and is expected to return in early 2022 (the “Leave”) and (b) he will also be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-287960","anchor_url":"https://secwatch.observer/filing/0001193125-21-287960#claim-e2cedd99e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521287960/0001193125-21-287960-index.htm"}]}